CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Slightly Bullish +25

CRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on Earnings

📉 Shares of CRISPR Therapeutics (CRSP) are down nearly 8% year-to-date and over 80% from their 2021 all-time highs.

👤 The company recently lost its COO, Julianne Bruno, raising concerns about leadership stability among investors.

🐻 Short interest is high at over 20 million shares, representing approximately 25% of the public float.

📅 Upcoming quarterly earnings are scheduled for May 14, 2025, expected to cause significant market volatility.

🏆 CRSP has topped earnings estimates for three consecutive quarters despite a difficult stock trajectory.

💰 The company possesses a strong balance sheet with sufficient cash to absorb further losses during development.

💊 Casgevy, a gene therapy developed alongside Vertex Pharmaceuticals (VRTX), shows promise despite a slow rollout.

📉 Cathie Wood recently trimmed her position by selling over $354,000 worth of shares but remains bullish long-term.

📊 The stock trades at a low price-to-book ratio of 1.69x, suggesting potential deep-value characteristics.

🌧️ Ark Invest CEO Cathie Wood views CRSP as a name that could rise stronger than others during an economic recession.

Bullish Signals
  • The company has topped earnings estimates for three straight quarters, demonstrating consistent operational performance despite market headwinds.
  • CRISPR Therapeutics maintains a strong balance sheet with ample cash on hand to absorb losses and fund future development.
  • The stock trades at a low price-to-book ratio of 1.69x, which some analysts interpret as a deep-value opportunity rather than a growth failure.
  • Cathie Wood highlights CRSP as a potential outperformer that could rise stronger than peers during an economic recession.
  • Casgevy has demonstrated significant promise in clinical trials, offering a potential revenue driver once the rollout accelerates.
Risk Factors
  • Shares are down nearly 8% year-to-date and more than 80% from their 2021 all-time highs, indicating severe investor skepticism.
  • The untimely resignation of COO Julianne Bruno has raised red flags regarding internal stability and management continuity.
  • High short interest of over 25% of the public float suggests a dominant bearish sentiment that could pressure the stock price.
  • The company is characterized by steep losses and a lack of needle-moving updates on existing products, making valuation difficult.
Full Analysis
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is the recent resignation of Chief Operating Officer Julianne Bruno, an event that has raised concerns among investors regarding internal stability and leadership continuity. The stock currently exhibits high short interest, with over 20 million shares sold short representing approximately 25% of the public float. This heavy bearish positioning suggests that short-sellers are betting against the company's near-term prospects ahead of its upcoming earnings report scheduled for May 14, 2025. Analysts note that while the company has topped earnings estimates for three consecutive quarters, the high short interest creates a potential environment for significant volatility if results diverge from low expectations. Despite the bearish sentiment, prominent investor Cathie Wood of Ark Invest maintains a bullish long-term view on gene editing technology. Although she recently trimmed her position by selling over $354,000 worth of shares, she still considers CRSP a potential performer that could outperform during an economic recession. The article highlights the company's strong balance sheet and its co-developed gene therapy, Casgevy (with Vertex Pharmaceuticals), as key assets that could drive a turnaround despite a lackluster rollout so far. The stock currently trades at a low price-to-book ratio of 1.69x, which some analysts view as indicative of a deep-value opportunity rather than a high-growth stock. With low analyst expectations and a valuation that appears discounted relative to its potential, the article suggests that CRSP could be a dangerous name to short given its cash reserves and innovative pipeline. The upcoming earnings report is expected to be a critical catalyst that could trigger a significant price movement for the gene-editing innovator.